SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors aggressively re-rate the stock, shifting from viewing it as a cyclical memory play to an essential, long-term AI infrastructure backbone amid persistent DRAM and NAND supply shortages. The community is heavily focused on the stock's parabolic trajectory and potential for further multiple expansion, with many discussing the impact of structural supply bottlenecks and the broader memory supercycle through 2027.

Everspin Technologies, Inc. engages in the provision of magnetoresistive random access memory (MRAM) solutions. Its products include Toggle MRAM, Spin-transfer Torque MRAM, TMR Sensors, and Embedded MRAM. The company was founded by Saied Tehrani on May 16, 2008 and is headquartered in Chandler, AZ.

Everspin Technologies Inc

Everspin Technologies is trending as investors bet on the companys specialized non-volatile MRAM as a critical component for emerging Edge AI and robotics infrastructure. The community is actively debating the stock's potential for a massive short squeeze due to its low float, while highlighting its strategic positioning in defense and aerospace supply chains.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors react to reports of impending leadership changes at the FDA, which the community views as a potential catalyst for clearing regulatory hurdles for the companys pipeline. The stock is seeing heightened activity fueled by bullish sentiment regarding ongoing international expansion, institutional accumulation, and a heavily squeezed short interest that investors believe could spark significant upside momentum.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is trending as investors focus on its integration into the TSMC COUPE platform for Co-Packaged Optics, a critical component for next-generation AI data center hardware. Community discussion is dominated by bullish sentiment regarding the company's long-term growth narrative in automotive and AI edge-sensing, despite ongoing debates about the timeline for mass adoption and historical stock price volatility.

Roundhill ETF Trust - Roundhill Memory ETF

Roundhill Memory ETF ($DRAM) is trending as investors rush to capitalize on the acute global shortage of memory chips, which has positioned DRAM and NAND as critical bottlenecks for AI infrastructure. The community is heavily focused on the ETF's concentrated exposure to memory leaders like SK Hynix, Samsung, and Micron, with bullish sentiment driven by multi-year demand forecasts for high-bandwidth memory.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is drawing significant investor interest as excitement builds around upcoming high-profile IPOs for SpaceX and Anthropic. Community discussions are heavily focused on the fund's direct exposure to these companies, with many participants debating the potential for a share price surge as IPO timelines approach.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending as investors react to positive Phase 3 flu vaccine data and an FDA Fast Track designation for its mRNA-4359 cancer therapy. The community is heavily focused on a potential short squeeze given the significant short interest and the company's broader expansion into oncology and respiratory combination vaccines.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is trending as market participants navigate extreme volatility driven by shifting geopolitical tensions, ongoing Middle East conflict, and uncertainty surrounding the Trump administration's trade and energy policies. The community is actively debating the merits of passive broad-market investing against the backdrop of potential black swan risks and concerns over long-term American economic stability.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a positive pre-BLA meeting with the FDA, where alignment on submission plans for sonelokimab in hidradenitis suppurativa has effectively de-risked the regulatory path toward a September BLA filing. The community is actively debating the stock's potential for a lucrative buyout, citing analyst upgrades and comparing the nanobody's efficacy and best-in-class label potential against existing market competitors.

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

Sui is seeing heavy retail and institutional volume, with the community actively debating whether current price action represents a prime accumulation opportunity or a signal to take profits. Traders are heavily focused on the coin's performance relative to other major L1 chains and are closely watching its ability to hold key technical levels amid high market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

These Catalysts are Triggering Massive Momentum

From enterprise AI clouds to breakthrough biotech catalysts, several emerging and mid-cap companies are capturing investor attention as transformative technologies accelerate commercialization and strategic partnerships deepen across industries. $XERI, $RXT, $NTHI, $GLE, $SOBR, $FLNC

Biotech’s Next Wave May Already be in Motion

The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction, late-stage clinical wins, and platform technologies are converging to reshape both valuations and patient outcomes. From aggressive insider buying ahead of critical data to blockbuster Phase 3 readouts redefining entire therapeutic categories, the market is signaling that the next cycle of winners may already be taking shape. $NTHI, $ERNA, $LLY, $NVO, $REGN, $MRNA

Where Executives Are Doubling Down on Their Companies’ Fortunes

As market participants are sifting through data, one signal often cuts through the noise: insiders putting real money to work. Executives and strategic stakeholders have been accumulating shares in meaningful size, ranging from six-figure buys to billion-dollar commitments. While insider buying is never a guarantee of upside, it frequently reflects conviction rooted in operational visibility, upcoming catalysts, or perceived undervaluation. $NTHI, $RIVN, $SRAD, $NWBI, $FGBI

Insider Signals and Potential Moonshots that Could Reset Valuations

Biotech and pharma markets are leading the way in a sharply selective environment at midday, where clinical data, insider conviction, and platform scalability are driving outsized moves while weaker narratives get left behind. $NTHI, $POET, $SDOT, $BDRX, $CLRB, $DOCN, $FSLY, $EWTX, $BLDP

Markets On Fire: Biotech Breakthroughs and AI Mega-Deals Move Wall Street

$CLRB, $NTHI, $BLZE, $DGXX, $VRDN, $CYTK are among today's leading stocks

NeOnc CEO Doubles Down with Insider Conviction Ahead of Critical Brain Cancer Data

NeOnc Technologies (NASDAQ:NTHI) is entering a high-stakes stretch and its CEO is making sure the market notices. In a series of open-market transactions, CEO and Executive Chairman Amir Heshmatpour has committed over $500,000 in recent weeks, bringing his total personal investment in the company to nearly $1 million over the past year. The timing is not subtle: it comes just as NeOnc approaches key clinical data readouts that could define its trajectory in the competitive field of brain cancer therapeutics.

NeOnc President Adds Shares

A fresh insider signal just hit the tape for NeOnc Technologies Holdings (NASDAQ:NTHI), and it’s the kind of move traders tend to notice.

Neonc Technologies (NASDAQ:NTHI) President Amir Heshmatpour Buys 10,000 Shares

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI - Get Free Report) President Amir Heshmatpour acquired 10,000 shares of the business's stock in a transaction on Thursday, April 23rd. The shares were...

Amir Heshmatpour Acquires 10,000 Shares of Neonc Technologies (NASDAQ:NTHI) Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI - Get Free Report) President Amir Heshmatpour acquired 10,000 shares of the firm's stock in a transaction dated Friday, April 10th. The shares were...

Neonc Technologies (NASDAQ:NTHI) President Purchases $25,950.00 in Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI - Get Free Report) President Amir Heshmatpour purchased 5,000 shares of the company's stock in a transaction on Thursday, April 9th. The shares were purchased at an average cost of $5.19 per share, with a total value of $25,950.00. Following the...

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.

NeOnc Technologies Holdings Inc.

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

NTHI
NeOnc Technologies Holdings Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest NTHI News

NTHINeOnc Technologies Holdings Inc.